MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), today announced the appointment of Veronica Gambillara Fonck ...

Hørsholm, Denmark, 14 November 2024 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") today announces its third quarter and year-to-date financial results for 2024. The report is available as an attachme ...

Combination vaccines can ease the logistics of vaccine management ... This has been apparent in recent outbreaks in the UK, ...

The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life ...

As anticipated, Evaxion has received a delisting determinationThe determination has been appealed by Evaxion requesting a hearing on the matter and seeking another 180-day extension to comply with ...

U.S-based Catalent, one of the world's largest contract manufacturers, made a huge windfall during the COVID-19 pandemic as ...

COVID-19 vaccination coverage has progressed unevenly throughout the world. Moreover, 1.01 and 1.43 doses for each person are ...

Belgium has solidified its position as a European leader in pharmaceutical research and development with a daily investment ...

New preclinical data demonstrates that CMV antigens identified with Evaxion’s AI-Immunology™ platform trigger targeted immune responses Results ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is ...

Comprehensive coverage of the hexavalent vaccine can protect against whooping cough and polio, averting disease resurgence, writes Esther Nakkazi.